| | Positive agreement received for approval of VIMOVO in Europe | | | AstraZeneca and POZEN Inc. today announced that VIMOVO (naproxen/ esomeprazole magnesium) 500/20 mg modified-release tablets has cleared an important regulatory milestone by receiving positive agreement for approval in 23 countries across the European Union (EU). This follows all 22 Concerned Member States agreeing with the assessment of the Netherlands Health Authority (MEB), acting as the Reference Member State for the Decentralised Procedure (DCP). It also results in a harmonised Summary of Product Characteristics (SmPC). The Member States will now pursue pricing and reimbursement and national approvals. | |  View full press release | | | This email has been sent via AstraZeneca's email alert service. Update your email preferences, unsubscribe from this service or contact us. | | | |
No comments:
Post a Comment